PMID: Food Funct. 2021 Oct 19 ;12(20):9829-9843. Epub 2021 Oct 19. PMID: 34664587 Abstract Title: An arabinogalactan fromattenuates DSS-induced chronic colitis in C57BL/6J mice associated with the modulation of intestinal barrier function and gut microbiota. Abstract: Ulcerative colitis (UC) is an incurable chronic inflammation of the enteric tract. The aim of this study was to investigate the protective effects of arabinogalactan fromon DSS-induced chronic colitis. A homogeneous arabinogalactan was isolated and purified from, named LBP-3, which mainly consisted of arabinose and galactose with a molar ratio of 1.00 : 0.82. LBP-3 treatment remarkably alleviated body weight loss, histopathological damage and the overproduction of pro-inflammatory cytokines and enzymes in UC mice. Additionally, the intestinal barrier integrity was partially recovered by the up-regulated expression ofand tight junction proteins. Moreover, the gut microbiota shift was reversed by LBP-3 administration by enriching potential probiotic bacteria (, Ruminococcaceae) and inhibiting the proliferation of harmful bacteria (, Enterobacteriaceae). Furthermore, SCFAs, as major metabolites of LBP-3 fermentation by gut microbiota, were also promoted so as to maintain relatively favorable intestinal homeostasis. Overall, our findings suggested LBP-3 fromcould be a potential therapeutic candidate against UCimproving intestinal barrier function and partially restoring gut microbiota and its metabolites.
read more
read more